Asian Petro Products and Exports Limited Overview
Asian Petroproducts and Exports Limited is a Vadodara-based micro-cap that was set up in 1991 to manufacture ethylene-oxide (EO) derivatives — ethanolamines (mono-, di- and tri-ethanolamine) and non-ionic ethoxylates — for refinery, fertiliser, textile, dye, pharmaceutical and detergent customers, and which describes itself as an early Indian producer of ethoxylates. After roughly a decade of near-dormancy (annual revenue below INR 2 crore through FY2019 and nil in FY2024), the company was recapitalised by its promoter family through warrants (2021–2023) and an INR 15.89 crore rights issue (late 2024), and has since rebuilt turnover to INR 67.5 crore in FY2026 and roughly INR 100 crore on a trailing-twelve-month basis. Its reported cost structure shows revenue is now overwhelmingly derived from low-margin trading of chemicals and plastic products rather than captive manufacturing. With a market value near INR 24 crore, a qualified audit opinion, and a further promoter-heavy preferential issue pending shareholder approval on 6 November 2026, it is best characterised as a promoter-controlled turnaround vehicle rather than an operating specialty-chemicals franchise.
The company's own description
In its FY2026 Management Discussion & Analysis (as reproduced by India Infoline), the company states, in substance, that it was incorporated in 1991, listed on BSE in 1994, began by manufacturing chemicals based on ethylene oxide, and regards itself as a pioneer of ethoxylate manufacture in India, serving refineries, fertiliser, textile, dye, pharmaceutical and detergent producers. It goes on to say that, as markets changed, it diversified into other chemical solutions, polymers and plastic products, with its major production breakthroughs occurring between 2002 and 2006; that its trading department has for many years been active in importing and exporting chemicals, allied products and plastic products; and that it subsequently began a trading business in plastic products and chemicals from its plant at Village Anjesar, Savli. The MD&A also states that infrastructure has been established to expand capacity from 4,000 MT to 10,000 MT, that the company reports a single "manufacturing" business segment, and that management expects business volumes to increase in the current year, barring unforeseen circumstances.
The rights-issue profile (Chittorgarh, 2024) adds that the plant sits on a 25-hectare site and that management's stated future strategy centres on brand equity, specialty formulations, geographic expansion and collaboration with technical experts.
Independent characterisation
The reported numbers tell a materially different story from the "manufacturing" self-description. In FY2023, INR 15.92 crore of the INR 16.79 crore expense base was "purchase of traded goods" against revenue of INR 16.66 crore. In FY2025, aggregator data codes INR 41.67 crore of costs as raw-material consumption — exactly equal to revenue of INR 41.67 crore — which implies a pass-through rather than value-adding conversion. In FY2026, the quarterly breakdowns for Q1–Q3 show cost lines labelled "purchase of traded goods" of INR 4.68 crore, INR 43.17 crore and INR 8.64 crore against revenue of INR 4.71 crore, INR 43.71 crore and INR 9.08 crore respectively. Cost of revenue was INR 66.48 crore against revenue of INR 67.50 crore for the full year (stockanalysis.com), a gross margin of roughly 1.5%. A manufacturing operation converting purchased EO or fatty alcohols into ethoxylates would ordinarily earn a materially higher conversion margin; a near-100% cost-to-revenue ratio is characteristic of commodity trading or back-to-back procurement.
The most defensible characterisation is therefore: (i) a legacy EO-derivatives manufacturer whose plant has, on the evidence of a near-zero depreciation charge (INR 0.00–0.03 crore per year in FY2022–FY2026) and fixed assets of roughly INR 2 crore, either been fully depreciated or largely idle; (ii) currently operating predominantly as a trader of chemicals and plastic products; with (iii) an optionality claim on reviving manufacturing using the expansion-ready infrastructure at Anjesar. Screener's AI extraction layer tracks premium-gated metrics titled "Trading sales as % of total revenue" and "Bond-to-Bond sales as % of total revenue", which suggests the annual report contains disclosures on trading share and customs-bonded (bond-to-bond) transactions; the values were not publicly accessible.
Business and revenue model
| Dimension | Assessment | Basis |
|---|---|---|
| Product vs service vs subscription vs licensing | ~100% product sales (physical goods); no service, subscription or licensing revenue disclosed | Revenue from operations line only; no other operating revenue in FY2025–FY2026 (stockanalysis.com) |
| Manufacturing vs trading split | Not publicly disclosed; cost structure indicates trading is dominant | Quarterly "purchase of traded goods" ≈ revenue (Vogue/BFSL) |
| Value-chain position | Downstream of EO producers (EO in India is produced by large integrated refiners/petrochemical companies); upstream of formulators in detergents, textiles, agrochemicals, oilfield and personal care | Product list; industry structure |
| Customer types | Industrial B2B buyers in refineries, fertilisers, textiles, dyes, pharmaceuticals, detergents, personal care | Company description; Screener summary |
| Customer concentration | — | — |
| Pricing model | Spot/contract commodity pricing; not disclosed | — |
| Working-capital model | Supplier-financed: payable days 148 vs debtor days 45 and inventory days 7 in FY2026, cash conversion cycle −97 days | Screener ratios |
End-markets served
The company names refineries (ethanolamines are used in gas sweetening and corrosion control), fertilisers, textiles and dyes (ethoxylates as wetting, levelling and scouring agents), pharmaceuticals, and detergents/personal care (lauryl alcohol ethoxylates and stearic acid ethoxylates as non-ionic surfactants and emulsifiers). It has also named plastic products as a traded category. No revenue split by end-market is disclosed.
Strategy
Stated corporate strategy (themes from filings)
The company's stated strategy, as expressed across the FY2026 MD&A and the 2024 rights-issue materials, has five themes, paraphrased here: (1) increasing business volumes in the current year, subject to unforeseen circumstances; (2) using already-established infrastructure to expand manufacturing capacity from 4,000 MT to 10,000 MT; (3) growing sales through brand equity and specialty formulations; (4) geographic expansion; and (5) collaboration with technical experts, with an emphasis on quality control. The MD&A also contains a generic macro statement to the effect that industrial targets will be hard to achieve unless the government lowers interest rates and improves availability of funds. The company holds no investor days and provides no strategy presentation.
Strategic initiatives announced in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Detail | Status |
|---|---|---|---|
| Oct–Dec 2024 | Rights issue (11:6 at INR 10) | INR 15.89 crore raised; objects: repay promoter unsecured loans, fund working capital, general corporate purposes | Completed; capital INR 24.56 crore |
| Dec 2024 onward | Revival of trading/sales operations | Revenue restarted in Q3 FY2025 and scaled to INR 67.5 crore in FY2026 | Ongoing |
| FY2026 | Statutory auditor change | Maheshwari & Co. replaced D B S & Associates | Completed |
| 30 May 2026 | Internal audit function | Internal auditor appointed | Completed |
| FY2025 auditor note | Accounting software upgrade | Company stated it was upgrading software to add audit-trail (edit log) functionality | Status not disclosed |
| Sep 2026 | Preferential issue (first attempt) | Board meeting scheduled for 9 Sep, rescheduled (8 Sep notice), and on 11 Sep the decision was deferred for further deliberation | Superseded |
| 15 Oct 2026 | Capital restructuring via preferential allotment | 96 lakh equity shares to promoters to convert unsecured loans (INR 9.6 crore); 1 crore convertible warrants to promoter group (up to INR 10 crore); 40 lakh equity shares to public-category investors (INR 4 crore); all at INR 10; total up to INR 23.6 crore; relevant date 7 Oct 2026 | EGM 6 Nov 2026 |
No partnerships, sustainability commitments, cost-reduction programmes with targets, or new business launches have been announced.
Medium-term targets and guidance
None. The company provides no quantitative revenue, margin, capacity-utilisation or return targets. The only forward-looking statement is the qualitative expectation of higher business volume. The 10,000 MT capacity figure is an infrastructure statement, not a dated commissioning target, and no capex budget for it has been disclosed.
Analytical view of the strategy
The pending preferential issue is the single most consequential strategic act. If fully approved and the warrants are exercised, share count rises from 2.46 crore to approximately 4.82 crore (+96%). Derived promoter holding would rise from ~1.40 crore shares (56.87%) to ~2.36 crore of 3.82 crore shares (~61.8%) after the equity tranches, and to ~3.36 crore of 4.82 crore shares (~69.7%) on full warrant conversion. Pricing at par (INR 10) is close to the current market price (~INR 9.8), so dilution is not at a steep discount, but it consolidates promoter control further while converting promoter debt into permanent capital. The fresh cash component (INR 4 crore immediately from public allottees plus warrant money, typically 25% upfront and 75% on conversion under SEBI ICDR) would fund working capital for the trading book, and potentially the dormant capacity expansion.
Products & Services
The company does not publish product specifications, capacities by product, price lists or launch dates. The catalogue below combines the company's disclosed product list (MarketsMojo company CV, TradingView, Screener) with general industry descriptions of each chemical's function. Specifications are generic industry characteristics, not company-specific data.
Ethanolamines (EO + ammonia derivatives)
| Product | Description and typical function | Target customers (company-named industries) | Company-specific specs / pricing | Launch year |
|---|---|---|---|---|
| Monoethanolamine (MEA) | Primary amine; used in acid-gas (H2S/CO2) scrubbing, as a corrosion inhibitor and as a chemical intermediate. Screener's summary calls it "monoethanolamide" — likely a transcription variance | Refineries, fertilisers, detergents | — | Not disclosed (original 1990s portfolio) |
| Diethanolamine (DEA) | Secondary amine; used in gas treating, as an intermediate for alkanolamides (detergent foam boosters) and in textile chemicals | Refineries, detergents, textiles | — | — |
| Triethanolamine (TEA) | Tertiary amine; used as a pH adjuster/emulsifier in personal care, cement grinding aid, textile and metalworking fluid additive | Detergents, personal care, textiles, pharmaceuticals | — | — |
Ethoxylates (EO + fatty substrate derivatives)
| Product | Description and typical function | Target customers | Company-specific specs / pricing | Launch year |
|---|---|---|---|---|
| Ethoxylates of various moles | Non-ionic surfactants whose hydrophilic–lipophilic balance is set by the number of moles of EO added; used as wetting agents, emulsifiers, dispersants | Textiles, dyes, agrochemicals, detergents | Mole range not disclosed | Company claims pioneering status in Indian ethoxylate manufacture |
| Lauryl alcohol ethoxylates | C12 fatty alcohol ethoxylates; core non-ionic surfactant in household and industrial detergents and a precursor for sulphated surfactants | Detergents, personal care | — | — |
| Stearic acid ethoxylates | Fatty-acid ethoxylates (PEG stearates); emulsifiers and thickeners in personal care, textile softeners and lubricants | Personal care, textiles, pharmaceuticals | — | — |
Diversified and traded categories
| Category | Description | Status |
|---|---|---|
| Other chemical solutions | Diversification undertaken in the 2002–2006 period per MD&A | Product names not disclosed |
| Polymers | Named as a diversification area | Product names not disclosed |
| Plastic products (trading) | Traded from the plant premises; also imported/exported by the trading department | Current principal revenue driver on cost-structure evidence; names, grades and volumes not disclosed |
| Chemicals (trading) | Import, export and domestic trading of chemicals and allied products | Volumes and counterparties not disclosed |
Brands, platforms and flagship offerings
No brand names, trademarks, or flagship SKUs are publicly disclosed. The 2024 rights-issue profile referred to a strategy of building "brand equity", but no brand has been named in any retrieved filing.
Financial Narrative
All figures INR crore, standalone, Ind AS, fiscal years ending 31 March. Primary sources: Directors' Reports (FY2023–FY2024 via India Infoline), BSE results as compiled by Vogue/BFSL (FY2021–FY2025), Screener/C-MOTS and stockanalysis.com/S&P (FY2026), company MD&A ratio table (FY2025–FY2026).
Income statement
Notes. FY2026 revenue: Screener's announcement summary of the BSE filing gives INR 6,750.30 lakh; InvestorFeed gives INR 6,695.30 lakh; stockanalysis.com gives INR 675.03 million. The INR 67.50 crore figure (matching two of three sources and the sum of reported quarters, INR 67.51 crore) is used. FY2026 other income and interest are sums of reported quarters; stockanalysis.com shows interest of INR 3.36 million (0.34 crore). FY2026 PAT of INR 120.99 lakh is from the company's MD&A. Gross profit is from stockanalysis.com (revenue less cost of revenue); its FY2022 revenue includes other revenue. EPS discrepancy: Vogue/BFSL shows FY2022 basic EPS −0.43 but diluted −0.03, and FY2023 basic 14.00 vs Directors' Report 0.14 — the FY2023 Directors' Report figure (INR 0.14) is used; Screener restates historic EPS for the rights issue (FY2024 −0.42, FY2022 −0.15), so per-share history is not comparable across sources.
Margins and growth
Revenue CAGR FY2022–FY2026 (4 years): approximately 273% per annum (from INR 0.35 crore to INR 67.50 crore) — mathematically correct but analytically meaningless given the near-zero base. The FY2023–FY2026 three-year CAGR is approximately 59%, matching Screener's 59%. The company's MD&A reports a net profit ratio of 1.81% for FY2026 versus −2.83% for FY2025; the small difference from the 1.8% above reflects the revenue denominator used. Screener reports an FY2022 OPM of −131%; the −134% above uses −0.47 operating profit from Research360 (Screener rounds to −0.46).
Quarterly trajectory (most recent eight quarters)
Source: Screener (C-MOTS). The prior-year quarters Q1–Q3 FY2025 had revenue of 0.00, 0.00 and 10.15 respectively. Note: a Business Standard-derived article describes Q1 FY2026 OPM as positive 3.82%; Screener shows −3.82% (operating profit −0.18 on revenue 4.71), which is arithmetically consistent — the article's sign appears erroneous. Q4 FY2026 profit was driven almost entirely by INR 1.19 crore of other income; operating profit was negative.
Trailing twelve months (Q2 FY2026–Q1 FY2027): revenue INR 100.50 crore; operating profit excl. OI INR −0.07 crore; other income INR 1.47 crore (matches Screener's flag); net profit INR 0.99 crore; EPS INR 0.40.
Balance sheet
Notes. Share capital and reserves FY2022–FY2025 from Vogue/BFSL; FY2026 reserves derived as FY2025 reserves plus FY2026 PAT (−12.80 + 1.21), consistent with Screener's rounded −12 and book value of INR 5.28 × 2.4558 crore shares = INR 12.97 crore. Borrowings FY2022–FY2024 are Screener's rounded figures; FY2025 and FY2026 borrowings are derived from the company's reported debt-equity ratios (0.08 and 0.11) multiplied by net worth, consistent with Screener's rounded "1". Cash, the short-/long-term debt split, and exact current assets/liabilities are not publicly disclosed in retrieved sources. Net working capital is derived from the company's current ratios (1.33 FY2025; 1.37 FY2026) applied to approximate current liabilities equal to other liabilities; treat as indicative only. Net worth was negative until the rights issue in FY2025.
Debt split and net debt. The short-term/long-term split of borrowings is not publicly disclosed. Net debt cannot be computed because cash is not disclosed. Screener's cash-flow data shows a net cash inflow of INR 8 crore in FY2025 (rights proceeds) and an outflow of INR 2 crore in FY2026, which suggests positive cash balances, but no balance-sheet cash figure was retrievable.
Cash flow
Source: Screener (rounded to whole crore). Capex approximated from investing outflows; FY2025 investing activity also included loans to and repayments from related entities. FY2025 financing inflow of ~INR 12 crore reflects INR 15.89 crore of rights proceeds net of repayment of promoter loans (a stated object of the issue). Cumulative FY2025–FY2026 operating cash burn of ~INR 5 crore occurred despite a reported profit in FY2026, reflecting working-capital build as trading volumes scaled.
Ratios
Notes. Company ratios are from the FY2026 MD&A table. ROE for FY2022–FY2024 is not meaningful because net worth was negative. ROA uses average total assets (Screener rounded figures), so FY2022–FY2024 values are approximate. ROIC derived as FY2026 EBIT incl. other income (1.57) × (1 − ~1% tax) ÷ invested capital (equity 12.97 + debt 1.43); excluding other income, ROIC is negative because operating EBIT was −0.08. Net debt/EBITDA is not computable (cash undisclosed; operating EBITDA negative). Debtor/inventory/payable days from Screener.
Commentary on trends, inflections and drivers
Revenue. The five-year revenue series is not a growth trend in the conventional sense; it is a sequence of restarts. FY2022's INR 0.35 crore and FY2024's nil revenue bracket an FY2023 burst of INR 16.66 crore that was almost entirely traded goods. The genuine inflection began in Q3 FY2025, coinciding with the rights issue: once the company had INR 15.89 crore of fresh equity and a positive net worth, it could carry working capital and supplier credit, and quarterly revenue moved into a INR 5–44 crore range. Quarterly volatility remains extreme (Q2 FY2026 INR 43.71 crore versus Q3 FY2026 INR 9.08 crore), which is consistent with lumpy, transaction-by-transaction trading rather than recurring production-led sales.
Margins. At the operating level, the company has not earned a meaningful positive margin in any year of the series. FY2026 operating profit excluding other income was approximately break-even (−INR 0.08 crore). The FY2026 reported profit of INR 1.21 crore is attributable to other income of INR 1.65 crore, of which INR 1.19 crore fell in Q4 FY2026. The nature of this other income (interest, write-backs, foreign-exchange gains, or one-off items) is not disclosed in retrieved sources and is a key diligence item; Screener flags the dependency explicitly.
Cost base. Employee costs have risen from INR 0.29 crore (FY2022) to roughly INR 0.65–0.68 crore, and "other expenses" from INR 0.19 crore to INR 0.95 crore (FY2025), reflecting the cost of maintaining listing, compliance and a trading operation. Against a gross margin of ~1.5%, the company needs annual revenue of roughly INR 100 crore merely to cover a INR 1.5 crore fixed cost base at the gross level — which is approximately where TTM revenue now sits.
Balance sheet. The rights issue converted a negative net worth of −INR 2.95 crore (FY2024) into +INR 11.76 crore (FY2025). Accumulated losses (reserves of −INR 11.59 crore) still consume nearly half of paid-up capital. Total assets jumped tenfold from ~INR 4 crore to ~INR 41 crore, funded mainly by trade payables (other liabilities ~INR 27–28 crore), which makes suppliers the company's principal financiers.
Cash flow. Operating cash flow turned negative as the business scaled (−INR 4 crore in FY2025, −INR 1 crore in FY2026). Screener's CFO/EBITDA ratios of 220% (FY2025) and 1,589% (FY2026) are mathematical artefacts of near-zero denominators and should be ignored. The October 2026 preferential plan — fresh cash of INR 4 crore from public investors, up to INR 10 crore from promoter warrants, and INR 9.6 crore of loan conversion — implies management expects further working-capital needs.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Segment metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Single segment revenue (INR Cr) | 0.35 | 16.66 | 0.00 | 41.67 | 67.50 |
Segment pre-tax profit (INR Cr) | -0.30 | 0.15 | -1.04 | -1.18 | 1.24 |
Segment PBT margin (%) | -85.7 | 0.9 | — | -2.8 | 1.8 |
YoY revenue growth (%) | -38.6 | 4,660.0 | -100.0 | — | 62.0 |
Contribution to total revenue (%) | 100 | 100 | 100 | 100 | 100 |
Revenue by Segment
| Activity proxy | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cost of goods as % of revenue | 94.3 | 95.6 | — | 100.0 | 98.5 |
Employee cost (INR Cr) | 0.29 | 0.49 | 0.55 | 0.68 | 0.65 |
Other expenses (INR Cr) | 0.19 | 0.36 | 0.47 | 0.95 | — |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 0.35 | 16.66 | 0.00 | 41.67 | 67.50 |
Other income (INR Cr) | 0.20 | 0.28 | 0.00 | 0.51 | 1.65 |
Gross profit (INR Cr) | 0.10 | 0.71 | -0.04 | -0.19 | 1.03 |
Operating profit / EBITDA excl. other income (INR Cr) | -0.47 | -0.10 | -1.02 | -1.63 | -0.08 |
EBITDA incl. other income (INR Cr) | -0.27 | 0.18 | -1.02 | -1.12 | 1.57 |
Depreciation (INR Cr) | 0.03 | 0.03 | 0.02 | 0.00 | 0.00 |
Operating income / EBIT incl. other income (INR Cr) | -0.30 | 0.15 | -1.04 | -1.12 | 1.57 |
Interest expense (INR Cr) | 0.00 | 0.00 | 0.00 | 0.05 | 0.33 |
Pre-tax income (INR Cr) | -0.30 | 0.15 | -1.04 | -1.18 | 1.24 |
Tax (INR Cr) | 0.00 | 0.04 | 0.00 | 0.00 | 0.01 |
Net income (INR Cr) | -0.30 | 0.11 | -1.04 | -1.18 | 1.21 |
EPS basic as reported (INR) | -0.43 | 0.14 | -1.20 | -0.48 | 0.49 |
EPS diluted as reported (INR) | -0.03 | 0.01 | -1.20 | -0.48 | 0.49 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 28.6 | 4.3 | — | -0.5 | 1.5 |
Operating (EBITDA excl. OI) margin (%) | -134.3 | -0.6 | — | -3.9 | -0.1 |
EBITDA margin incl. OI (%) | -77.1 | 1.1 | — | -2.7 | 2.3 |
Net margin (%) | -85.7 | 0.7 | — | -2.8 | 1.8 |
Revenue growth YoY (%) | -38.6 | 4,660.0 | -100.0 | — | 62.0 |
Income Statement and Per-Share Data (Quarterly)
| Metric | Q4FY2025 | Q1FY2026 | Q2FY2026 | Q3FY2026 | Q4FY2026 | Q1FY2027 |
|---|---|---|---|---|---|---|
Revenue (INR Cr) | 31.52 | 4.71 | 43.71 | 9.08 | 10.01 | 37.70 |
Operating profit excl. OI (INR Cr) | -0.48 | -0.18 | 0.05 | 0.07 | -0.02 | -0.17 |
Other income (INR Cr) | 0.51 | 0.37 | -0.05 | 0.14 | 1.19 | 0.19 |
Interest (INR Cr) | 0.05 | 0.05 | 0.05 | 0.11 | 0.12 | 0.12 |
PBT (INR Cr) | -0.02 | 0.14 | -0.05 | 0.10 | 1.05 | -0.10 |
Net profit (INR Cr) | -0.02 | 0.14 | -0.05 | 0.10 | 1.04 | -0.10 |
EPS (INR) | -0.01 | 0.06 | -0.02 | 0.04 | 0.42 | -0.04 |
OPM (%) | -1.52 | -3.82 | 0.11 | 0.77 | -0.20 | -0.45 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Equity share capital (INR Cr) | 6.92 | 7.70 | 8.67 | 24.56 | 24.56 |
Reserves and surplus / other equity (INR Cr) | -8.95 | -10.58 | -11.62 | -12.80 | -11.59 |
Total equity / net worth (INR Cr) | -2.03 | -2.88 | -2.95 | 11.76 | 12.97 |
Total borrowings (INR Cr) | 3 | 2 | 4 | 0.94 | 1.43 |
Other liabilities incl. trade payables (INR Cr) | 1 | 2 | 3 | 28 | 27 |
Total assets (INR Cr) | 2 | 2 | 4 | 41 | 42 |
Fixed assets (INR Cr) | 0 | 0 | 2 | 2 | 2 |
Goodwill and intangibles (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Net working capital (INR Cr, derived) | — | — | — | 8.6 | 10.2 |
Book value per share (INR) | — | — | — | 4.79 | 5.28 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 0 | 1 | 0 | -4 | -1 |
Investing cash flow (INR Cr) | 0 | 0 | -2 | 0 | -1 |
Financing cash flow (INR Cr) | 0 | -1 | 1 | 12 | 0 |
Net cash flow (INR Cr) | 0 | 0 | 0 | 8 | -2 |
Capex (INR Cr, approx.) | 0 | 0 | 2 | 0 | 1 |
Free cash flow (INR Cr) | 0 | 1 | -1 | -4 | -1 |
Dividends paid (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) | — | — | — | -26.79 | 9.79 |
ROA (%, derived) | -15.0 | 5.5 | -34.7 | -5.2 | 2.9 |
ROCE (%, company) | — | — | — | -23.49 | 12.60 |
ROCE (%, Screener) | -21 | 19 | -166 | -17 | 12 |
ROIC incl. other income (%, derived) | — | — | — | — | 10.8 |
Current ratio (x) | — | — | — | 1.33 | 1.37 |
Debt to equity (x) | — | — | — | 0.08 | 0.11 |
Interest coverage, EBIT incl. OI / interest (x) | — | — | — | -22.4 | 4.8 |
Asset turnover (x, derived) | 0.17 | 8.33 | 0.00 | 1.85 | 1.63 |
Net capital turnover (x, company) | — | — | — | 4.38 | 6.25 |
Trade receivables turnover (x, company) | — | — | — | 2.92 | 3.77 |
Trade payables turnover (x, company) | — | — | — | 2.99 | 2.52 |
Debtor days | 1,783 | 28 | — | 239 | 45 |
Inventory days | 0 | 0 | — | — | 7 |
Payable days | — | — | — | — | 148 |
Cash conversion cycle (days) | 1,783 | 28 | — | 239 | -97 |
Revenue by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total revenue (INR Cr) | 0.00 | 41.67 | 67.50 |
Share Price & Returns
| Horizon | Return | Source / note |
|---|---|---|
1 year | +10% | Screener (to Oct 2026); Bajaj Finserv shows +1.16% to 14 Aug 2026 |
3 years (CAGR) | −5% | Screener |
5 years (CAGR) | −25% | Screener |
Since IPO | −16.4% | S&P via Simply Wall St (as of May 2025) |
Valuation Multiples
| Multiple | APEL | Peer reference | Basis |
|---|---|---|---|
Market cap (INR Cr) | 24.1 | India Glycols ~6,762 (May 2026) | Screener; Arihant |
P/E (TTM) | 24.3x | — | TTM EPS INR 0.40 |
P/B | 1.86x | Value Research cited peer median P/B of 1.02x (Apr 2026) | Book value INR 5.28 |
EV/Sales (TTM) | ~0.25x | — | EV ≈ market cap 24.1 + debt ~1.4 (cash undisclosed, so EV is an upper bound) ÷ TTM revenue 100.5 |
EV/EBITDA (TTM) | Not meaningful excl. OI (EBITDA −0.07); ~18x incl. OI (EBITDA ~1.40) | — | Derived |
Dividend yield | 0% | — | No dividends |
Capital Markets Data and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Shares outstanding (crore) | 0.69 | 0.77 | 0.87 | 2.46 | 2.46 |
Paid-up capital (INR Cr) | 6.92 | 7.70 | 8.67 | 24.56 | 24.56 |
Promoter holding (%) | 51.16 | 56.08 | 56.17 | 56.42 | 56.87 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Share Price & Returns by Date
| Date | Instrument | Size | Price | Allottees | Outcome |
|---|---|---|---|---|---|
30 Nov 2021 | Convertible warrants | 23,87,500 | — | Promoter & promoter group | 9,70,000 converted 13 Apr 2023; treatment of remaining 14,17,500 not disclosed (likely lapsed or converted earlier) |
11 Nov – 5 Dec 2024 | Rights issue 11:6 | ~1.59 crore shares; INR 15.89 crore | INR 10 (par) | Existing shareholders (record date 30 Oct 2024) | Completed; capital INR 8.67 crore → INR 24.56 crore |
Proposed (EGM 6 Nov 2026) | Equity shares (loan conversion) | 96,00,000 | INR 10 | Promoters | Pending |
Proposed | Convertible warrants | 1,00,00,000 | INR 10 | Promoter group | Pending |
Proposed | Equity shares | 40,00,000 | INR 10 | Public-category investors | Pending |
Analyst Conclusions
Management guidance
Management offers only a qualitative expectation of higher business volume in the current year, barring unforeseen circumstances (FY2026 MD&A). No revenue, margin, capacity-commissioning or capex guidance exists. Consensus growth expectations: none (no analyst coverage).
Bull case
-
The operating platform has been rebuilt and is scaling. Revenue went from nil (FY2024) to INR 67.5 crore (FY2026) to ~INR 100.5 crore TTM, and Q1 FY2027 revenue of INR 37.70 crore was 8x the prior-year quarter. At ~0.25x EV/Sales, any margin improvement would be highly accretive to a INR 24 crore market cap: a sustained 2% net margin on INR 100 crore would be INR 2 crore of profit, or ~INR 0.81 per share on the current base.
-
Balance-sheet clean-up is under way. The 2024 rights issue restored positive net worth, and the proposed INR 9.6 crore promoter-loan conversion would eliminate the main interest-bearing liability, while fresh warrant money supports working capital without bank debt.
-
Hidden asset value and manufacturing optionality. A 25-hectare EO-derivative site with infrastructure for 10,000 MT is carried at ~INR 2 crore of fixed assets. A restart of ethoxylate manufacturing, even partially, would lift gross margins from ~1.5% toward conversion-level margins earned by producers.
Bear case
-
There is no operating profit. Operating profit excluding other income has been negative in every year from FY2022 to FY2026 and again in Q1 FY2027; FY2026's reported profit exists only because of INR 1.65 crore of undisclosed other income.
-
Minority shareholders bear the dilution. The proposed issue would nearly double the share count and lift promoter ownership toward ~70% (derived), shrinking free float in a stock with no institutional holders, while the at-par pricing gives promoters cheap optionality via warrants.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable | What to watch |
|---|---|---|
| 6 Nov 2026 | EGM vote on preferential issue | Approval margin; any public-allottee identities; in-principle BSE approval |
| Nov 2026 | Q2 FY2027 results | Whether revenue sustains above INR 30 crore per quarter and operating margin turns positive |
| Ongoing | Warrant subscription money | Upfront 25% receipt and use of proceeds |
| FY2026 annual report | Basis for FY2026 qualification; nature of other income; promoter loan balance; trading vs manufacturing split | Reconciliation of "debt-free" statement with INR 9.6 crore loan conversion |
| Feb 2027 | Q3 FY2027 results | Interest cost after loan conversion |
| May 2027 | FY2027 audited results | Whether the audit opinion becomes unqualified under the new auditor and internal-audit regime |
| Any time | Capex announcement for 10,000 MT capacity | Budget, timeline, environmental clearances, EO supply arrangement |
| Any time | Related-party transactions | Further loans to Brijlaxmi or World Tradimpex entities |
Analyst verdict
Asian Petroproducts and Exports Limited should not be analysed as a specialty-chemicals company. It is a promoter-controlled listed shell that has been recapitalised and put back to work, primarily as a trader of chemicals and plastic products, with a legacy ethylene-oxide-derivatives plant whose economic contribution is currently invisible in the accounts. The evidence is consistent across sources: cost of goods near 98–100% of revenue, depreciation close to zero, operating losses in every year of the five-year window, and a FY2026 profit that rests entirely on other income.
The revival has been real at the top line. Revenue has scaled from nothing to roughly INR 100 crore on a trailing basis, the 2024 rights issue repaired a negative net worth, and the supplier-financed working-capital model has allowed volume growth with limited equity. The separation of chair and MD, a clean secretarial compliance report, an auditor change and the appointment of an internal auditor indicate some effort at remediation.
Against that, the quality of information is the binding constraint. Two consecutive qualified audit opinions, tax-compliance lapses, an absence of internal audit and audit trails until recently, intra-group loans without repayment terms, and contradictory narrative statements (a "debt-free" claim alongside a proposed conversion of INR 9.6 crore of promoter loans) mean that investors cannot place high confidence in reported figures. The pending preferential issue will further concentrate ownership in the promoter family at par value.
At roughly INR 24 crore of market value, 1.9x book and 0.25x TTM sales, the stock prices in neither the asset optionality of the Anjesar site nor the governance discount fully; it is effectively a binary call on whether the promoters convert the plant and the fresh capital into a genuinely value-adding manufacturing business. Until the company delivers a positive operating margin for several consecutive quarters, an unqualified audit, and a funded capacity plan, the appropriate stance is to treat it as a speculative, high-risk micro-cap suitable only for monitoring, not as an investable operating franchise.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Category | Tenure / key dates | Notes |
|---|---|---|---|---|
Jaykishor Chaitanyakishor Chaturvedi | Managing Director (DIN 00467706) | Executive, Promoter | MD per S&P data since Sep 2019 (earlier MD term to 2018); Chairman until 30 May 2024 | Largest shareholder: 24.91% directly (61,18,554 shares); signs company filings |
Jashwant Bhatt | Chairman | Independent (listed as independent director in 2022) | Appointed Chairman 30 May 2024; reappointed 30 May 2026 | Chair/MD separation since May 2024 |
Siddharth Jaykishor Chaturvedi | Director | Non-independent, Promoter group | Listed as director since at least Mar 2022 | Holds 8.73% (21,43,385 shares) |
Nupur Chaturvedi | Director | Non-independent (promoter family) | Listed as director as of Mar 2022 | — |
Devindersingh Bhumra | Director | Independent | Appointed 1 Oct 2022 | — |
Ankur Jaykishor Chaturvedi | Chief Financial Officer | KMP, Promoter group | — | Holds 1.30% (3,18,192 shares) |
Anjali Gurnani | Company Secretary & Compliance Officer | KMP | ~7.2 years (S&P, Nov 2025) | — |
Rajendra Kumar Singhal | Former Independent Director | Independent | Resigned 18 May 2022 | Departure |
“—” = not publicly disclosed.
Directors' Remuneration
| Person | Salary | Bonus | Stock / options | Total | Period |
|---|---|---|---|---|---|
Jaykishor Chaturvedi (MD) | INR 2.40 million (100% salary) | 0 | 0 | INR 2.40 million | Latest S&P-reported fiscal year (likely FY2025) |
Company Secretary | — | — | — | INR 0.555 million | Same |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
18 May 2022 | Rajendra Kumar Singhal resigned as independent director | Reason not disclosed |
1 Oct 2022 | Devindersingh Bhumra appointed independent director | Board refresh |
30 May 2024 | Jashwant Bhatt appointed Chairman; J. K. Chaturvedi relinquishes chair | Separation of chair and MD |
FY2026 (by Feb 2026) | Statutory auditor change from D B S & Associates to Maheshwari & Co. | Followed FY2025 qualified opinion; reasons not disclosed in retrieved sources |
30 May 2026 | Jashwant Bhatt reappointed; internal auditor appointed | Addresses FY2025 CARO observation that internal audit was not implemented |
Shareholding Trend
| Holder category | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Promoter and promoter group (%) | 51.16 | 56.08 | 56.17 | 56.42 | 56.87 |
Public (%) | 48.84 | 43.92 | 43.83 | 43.58 | 43.15 |
FII (%) | 0 | 0 | 0 | 0 | 0 |
DII / mutual funds (%) | 0 | 0 | 0 | 0 | 0 |
Number of shareholders | 14,131 | 14,381 | 15,091 | 16,294 | 16,461 |
Major Shareholders
| Rank | Holder | Category | Shares | Stake (%) |
|---|---|---|---|---|
| 1 | Jaykishor Chaturvedi | Promoter | 61,18,554 | 24.91 |
| 2 | Chaturvedi (HUF) / J. K. Chaturvedi (HUF) | Promoter group | 26,39,370 – 27,49,874 | 10.75 – 11.20 |
| 3 | Siddharth Jaykishor Chaturvedi | Promoter group | 21,43,385 | 8.73 |
| 4 | Kailashben Ashokkumar Patel | Public | 14,12,480 | 5.75 (MarketsMojo also cites 6.22%) |
| 5 | Brijlaxmi Leasing and Finance Limited | Classified as promoter by Vogue/BFSL EOD data; not in Emkay's promoter list | ~14,10,000 | 5.74 |
| 6 | World Tradeimpx Ltd | Promoter group (per Bajaj Finserv/Vogue) | 12,24,500 | 4.99 |
| 7 | Ashish Chugh | Public | 5,00,000 | 2.04 |
| 8 | Ankur Jaykishor Chaturvedi | Promoter group | 3,18,192 | 1.30 |
| 9 | Glaston Mario Menezes | Public | 2,51,110 | 1.02 |
| 10 | Chaitanya K Chaturvedi | Promoter group | 0 | 0.00 |
Competitive Landscape
Key Competitors
| # | Competitor | Overlap with APEL | FY2026 revenue (INR Cr) | Positioning relative to APEL |
|---|---|---|---|---|
| 1 | Galaxy Surfactants Ltd | Fatty alcohol ethoxylates and other non-ionic/anionic surfactants for home and personal care | 5,248 (consolidated) | Scale leader in Indian oleochemical surfactants; ~78x APEL's revenue |
| 2 | India Glycols Ltd | EO and EO derivatives (ethoxylates, glycols), bio-based ethoxylates/amines | 4,211 (consolidated sales, Business Standard); Anand Rathi shows net sales of 9,827 on a different basis | Integrated EO producer from bio-ethanol; dominant domestic EO-derivative player |
| 3 | Balaji Amines Ltd | Amines (methyl/ethyl amines and derivatives) — adjacent to ethanolamines | 1,425 (Business Standard); 1,454 consolidated per other filing summaries | Specialist amine producer; zero standalone debt |
| 4 | Reliance Industries (petrochemicals) | Domestic EO/MEG producer; upstream supplier to ethoxylators | — | Feedstock supplier, not a direct product competitor |
| 5 | Indian Oil Corporation (Panipat petrochemicals) | Domestic EO/MEG producer | — | Feedstock supplier |
| 6 | BASF India Ltd | Imported/locally marketed ethanolamines and surfactants | — | Global major with distribution in India |
| 7 | Clariant Chemicals (India) Ltd | Specialty surfactants and ethoxylates for textiles and agro | — | Specialty-focused MNC subsidiary |
| 8 | Alkyl Amines Chemicals Ltd | Amines and derivatives | — | Specialist amines producer |
| 9 | Diamines & Chemicals Ltd | Ethyleneamines | — | Small listed amines producer |
| 10 | Unlisted Indian ethoxylators and chemical traders (Gujarat/Maharashtra clusters) | Ethoxylates and traded chemicals/plastics | — | Most direct competitors for APEL's current trading model |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | APEL | Galaxy Surfactants | India Glycols | Balaji Amines |
|---|---|---|---|---|
Revenue (INR Cr) | 67.5 | 5,248.3 | 4,211.4 | 1,425.0 |
Revenue growth YoY (%) | 62.0 | 24.3 | 11.8 | 2.0 |
Operating / EBITDA margin (%) | -0.1 (excl. OI) | ~9.4 (EBITDA 4,974 mn / revenue 52,704 mn) | — | 18.63 |
Net profit (INR Cr) | 1.21 | 267.38 | 292.76 (consolidated) | 167.20 |
Net margin (%) | 1.8 | 5.1 | ~7.0 | ~11.7 |
Market cap (INR Cr) | ~24 | — | ~6,762 (May 2026) | — |



